Qualifications

• BAppSc Biotech

Projects (5)

Current (5)

• 

  A novel gel for targeting vaginal inflammation to prevent HIV transmission

• 

  Antimicrobial and immune modulatory effects of vaginal microbiota metabolites

• 

  Development of hydrogel based intravaginal drug delivery device

• 

  Impact of a vaginal microbiota metabolite on epithelium integrity and HIV susceptibility

• 

  Targeting novel sites on reverse transcriptase for HIV treatment and prevention

Publications (17)

2022 (2)

• Lactic acid from vaginal microbiota enhances cervicovaginal epithelial barrier integrity by promoting tight junction protein expression.
  Delgado-Diaz DJ, Jesaveluk B, Hayward JA, Tyssen D, Alisoltani A, Potgieter M, Bell L, Ross E, Iranzadeh A, Allali I, Dabee S, Barnabas S, Gamieldien H, Blackburn JM, Mulder N, Smith SB, Edwards VL, Burgener AD, Bekker LG, Ravel J, Passmore JS, Masson L, Hearps AC, Tachedjian G
  Microbiome. 2022 Aug; 10(1):141
• The Impact of Over-The-Counter Lactic Acid Containing Vaginal Gels on the Integrity and Inflammatory State of the Vaginal Epithelium in vitro.
  Tyssen D, Hearps AC, Guntur K, Masson L, Cook S, Moulton SE, Ravel J, Bradshaw CS, Ayehunie S, Tachedjian G
  Front Reprod Health. 2022 Jun; 4:915948

2020 (1)

• Distinct Immune Responses Elicited From Cervicovaginal Epithelial Cells by Lactic Acid and Short Chain Fatty Acids Associated With Optimal and Non-optimal Vaginal Microbiota.
  Delgado-Diaz DJ, Tyssen D, Hayward JA, Gugasyan R, Hearps AC, Tachedjian G
  Front Cell Infect Microbiol. 2020 Jan; 9:446

2019 (2)

• A 30 kDa polyethylene glycol-enfuvirtide complex enhances the exposure of enfuvirtide in lymphatic viral reservoirs in rats.
  Kaminskas LM, Williams CC, Leong NJ, Chan LJ, Butcher NJ, Feeney OM, Porter CJH, Tyssen D, Tachedjian G, Ascher DB
  Eur J Pharm Biopharm. 2019 Mar; 137:218-226
• Molecular Dissection of an Inhibitor Targeting the HIV Integrase Dependent Pre-Integration Complex Nuclear Import.
  Wagstaff KM, Headey S, Telwatte S, Tyssen D, Hearps AC, Thomas DR, Tachedjian G, Jans DA
  Cell Microbiol. 2019 Jan; 21(1):e12953

2018 (1)

• Anti-HIV-1 Activity of Lactic Acid in Human Cervicovaginal Fluid.
  Tyssen D, Wang YY, Hayward JA, Agius PA, DeLong K, Aldunate M, Ravel J, Moench TR, Cone RA, Tachedjian G
  mSphere. 2018 Jul; 3(4):e00055-18

2017 (1)

• Vaginal lactic acid elicits an anti-inflammatory response from human cervicovaginal epithelial cells and inhibits production of pro-inflammatory mediators associated with HIV acquisition.
  Hearps AC, Tyssen D, Srbinovski D, Bayigga L, Diaz DJD, Aldunate M, Cone RA, Gugasyan R, Anderson DJ, Tachedjian G
  Mucosal Immunol. 2017 Apr; 10(6):1480-1490

2015 (1)

• Identification of mechanistically distinct inhibitors of HIV-1 reverse transcriptase through fragment screening.
  La J, Latham CF, Tinetti RN, Johnson A, Tyssen D, Huber KD, Sluis-Cremer N, Simpson JS, Headey SJ, Chalmers DK, Tachedjian G
  PNAS. 2015 May; 112(22):6979-6984

2013 (1)

• Vaginal concentrations of lactic acid potently inactivate HIV.
  Aldunate M, Tyssen D, Johnson A, Zakir T, Sonza S, Moench T, Cone R, Tachedjian G
  J Antimicrob Chemother. 2013 May; 68(9):2015-25

2011 (2)

• SPL7013 Gel (VivaGel®) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans.
  Price CF, Tyssen D, Sonza S, Davie A, Evans S, Lewis GR, Xia S, Spelman T, Hodsman P, Moench TR, Humberstone A, Paull JR, Tachedjian G
  PLoS One. 2011 Sep; 6(9):e24095
• Virucidal activity of the dendrimer microbicide SPL7013 against HIV-1.
  Telwatte S, Moore K, Johnson A, Tyssen D, Sterjovski J, Aldunate M, Gorry PR, Ramsland PA, Lewis GR, Paull JR, Sonza S, Tachedjian G
  Antiviral Res. 2011 Jun; 90(3):195-199

2010 (2)

• Structure activity relationship of dendrimer microbicides with dual action antiviral activity.
  Tyssen D, Henderson SA, Johnson A, Sterjovski J, Moore K, La J, Zanin M, Sonza S, Karellas P, Giannis MP, Krippner G, Wesselingh S, McCarthy T, Gorry PR, Ramsland PA, Cone R, Paull JR, Lewis GR, Tachedjian G
  PLoS One. 2010 Aug; 5(8):e12309
• Ubisol-Aqua: coenzyme Q10 prevents antiretroviral toxic neuropathy in an in vitro model.
  Cherry CL, Mobarok M, Wesselingh SL, Fain R, Weinstock S, Tachedjian G, Srivastava S, Tyssen DP, Glass JD, Hooker DJ
  Curr HIV Res. 2010 Apr; 8(3):232-239

2009 (1)

• Enhancement of human immunodeficiency virus type 1 replication is not intrinsic to all polyanion-based microbicides.
  Sonza S, Johnson A, Tyssen D, Spelman T, Lewis GR, Paull JR, Tachedjian G
  Antimicrob Agents Chemother. 2009 Aug; 53(8):3565-3568

2007 (1)

• N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.
  Yap SH, Sheen CW, Fahey J, Zanin M, Tyssen D, Lima VD, Wynhoven B, Kuiper M, Sluis-Cremer N, Harrigan PR, Tachedjian G
  PLoS Med. 2007 Dec; 4(12):e335

1992 (1)

• Clinical effects and in vitro studies of trifluorothymidine combined with interferon-alpha for treatment of drug-resistant and -sensitive herpes simplex virus infections.
  Birch CJ, Tyssen DP, Tachedjian G, Doherty R, Hayes K, Mijch A, Lucas CR
  J Infect Dis. 1992 Jul; 166(1):108-112

1990 (1)

• Investigation of topoisomerase inhibitors for activity against human immunodeficiency virus: inhibition by coumermycin A1
  Tachedjian G, Tyssen D, Locarnini S, Gust I, Birch C
  Antivir Chem Chemother. 1990 Jul; 12:131-138

News Articles (6)

2018 (2)

• Bumper turnout for Student Night
• Professor Tachedjian chairs session at AIDS 2018

2017 (1)

• Protection for women at high risk of HIV

2015 (2)

• HIV research attracts Nature's interest
• Burnet discovery of building blocks for new drug classes to prevent and treat HIV

2012 (1)

• Microbicides: enabling women to protect themselves against HIV